HOLON, Israel, Oct. 2,
2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)
(TASE: CGEN) a clinical-stage cancer immunotherapy company and a
pioneer in computational target discovery, today announced
that the Japanese Patent Office has granted Compugen a patent for
treating cancer with a triple combination of any anti- PVRIG
antibody with any anti-TIGIT and anti-PD-1 antibody.
Japanese patent No. JP7348072B2, titled "Triple Combination
Antibodies Therapies" augments previously issued patent in
Japan by expanding and protecting
Compugen's differentiated and leading triple blockade of the DNAM-1
axis with any anti-PVRIG in combination with any anti-TIGIT and
anti-PD-1 antibody.
"We are delighted to strengthen our patent portfolio supporting
our leadership in blocking three pathways of the DNAM-1 axis,
PVRIG, TIGIT and PD-1", said Anat
Cohen-Dayag, Ph.D., President, and Chief Executive Officer
of Compugen. "Addressing resistance to immunotherapy is a
substantial unmet medical need and we are executing on a
differentiated clinical strategy to evaluate the benefit of our
chemotherapy free, triple immunotherapy combination of COM701,
COM902 and pembrolizumab to treat patients with cancer."
Japanese patent No. JP7348072B2 is expected to expire no
earlier than June 2038.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2
development by AstraZeneca through a license agreement for the
development of bi-specific and multi-specific antibodies. In
addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance. The most
advanced program, COM503 is in IND enabling studies. COM503 is a
potential first-in-class, high affinity antibody which blocks the
interaction between IL-18 binding protein and IL-18, thereby
freeing natural IL-18 to inhibit cancer growth in the tumor
microenvironment. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended, and the safe-harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on the current beliefs,
expectations, and assumptions of Compugen. Forward-looking
statements can be identified using terminology such as "'will,"
"may," "expects," "anticipates," "believes," "potential," "plan,"
"goal," "estimate," "likely," "should," "confident," and "intends,"
and similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking
statements include, but are not limited to, statements regarding
the expected expiration date of the patent in Japan. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance, or
achievements of Compugen to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Among these risks: patent terms may be
inadequate to protect our competitive position on our product
candidates for an adequate amount of time, and changes to the
patent law in Japan and other
jurisdictions could diminish the value of patents in general,
thereby impairing our ability to protect our product candidates.
These risks and other risks are more fully discussed in the "Risk
Factors" section of Compugen's most recent Annual Report on Form
20-F as filed with the Securities and Exchange Commission (SEC) as
well as other documents that may be subsequently filed by Compugen
from time to time with the SEC. In addition, any forward-looking
statements represent Compugen's views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Compugen does not assume any obligation to
update any forward-looking statements unless required by
law.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-expands-intellectual-property-with-new-japanese-patent-for-the-triple-combination-of-any-anti-pvrig-tigit-and-pd-1-antibody-for-the-treatment-of-cancer-301944287.html
SOURCE Compugen Ltd.